Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Snai1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Snai1 siRNA is a research-stage small interfering RNA (siRNA) designed to silence the expression of the SNAI1 gene, which encodes the Snail-1 transcription factor. Snail-1 is a critical regulator of the epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndMT), processes associated with cancer metastasis, fibrosis, and inflammation. In preclinical oncology models, Snai1 siRNA has been investigated for its ability to reduce tumor invasiveness and stemness in cancers such as ovarian, breast, and pancreatic carcinoma. More recently, it has been explored as a potential therapeutic for right ventricular failure secondary to pulmonary hypertension by inhibiting inflammatory pathways and fibrosis. It is primarily used as a laboratory research tool and is available through commercial reagent suppliers.
- Other names
- SNAI1 siRNASNAI-1 siRNASNAI 1 siRNASnail-1 siRNASnail1 siRNASnail 1 siRNASnail siRNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)SNAI1 (Snail family transcriptional repressor 1)
Beyond the preview
Go deeper on Snai1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Snai1 siRNA.